Th9 cells represent a new paradigm of CD4+ T cells endowed with a superb antitumor ability. Lu Y, Wang Q, Xue G, Bi E, Ma X, Wang A, Qian J, Dong C. and Yi Q. Cancer Cell 33:1048-1060, 2018.
Cholesterol induces CD8+ T-cell exhaustion in the tumor microenvironment. Ma XZ, Bi EG, Lu Y, Su P, Huang CJ, Liu LT, Wang Q, Yang MJ, Kalady MF, Qian JF, Zhang AJ, Gupte AA, Hamilton DJ, Zheng CY, Yi Q. Cell Metab 30:143-156, 2019.
MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma. Wang Q, Zhao DY, Xian M, Wang Z, Bi EG, Su P, Qian JF, Ma XZ, Yang MJ, Liu LT, Zu YL, Pingali SR, Chen KF, Cai Z, Yi Q. Blood 136:2557-2573, 2020.
CD36-mediated ferroptosis dampens intratumoral CD8+ T-cell effector function and impairs their antitumor ability. Ma XZ, Xiao LL, Ye LQ, Su P, Liu LT, Bi EG, Wang Q, Yang MJ, Qian JF, Yi Q. Cell Metab 33:1-12, 2021.
Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma. Li, R, Zheng, C, Wang, Q, Bi, E, Yang, M, Hou, J, Fu, W, Yi, Q & Qian, J 2021, , Haematologica, vol. 106, no. 3, pp. 838-846. https://doi.org/10.3324/haematol.2019.236836
Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma. Li, Z, Liu, H, He, J, Wang, Z, Yin, Z, You, G, Wang, Z, Davis, RE, Lin, P, Bergsagel, PL, Manasanch, EE, Wong, STC, Esnaola, NF, Chang, JC, Orlowski, RZ, Yi, Q & Yang, J 2021, , Cell Metabolism, vol. 33, no. 1, pp. 78-93.e7. https://doi.org/10.1016/j.cmet.2020.12.011
Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Tseng, HC, Xiong, W, Badeti, S, Yang, Y, Ma, M, Liu, T, Ramos, CA, Dotti, G, Fritzky, L, Jiang, JG, Yi, Q, Guarrera, J, Zong, WX, Liu, C & Liu, D 2020, Nature Communications, vol. 11, no. 1, 4810. https://doi.org/10.1038/s41467-020-18444-2
Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9. Liu, L, Bi, E, Ma, X, Xiong, W, Qian, J, Ye, L, Su, P, Wang, Q, Xiao, L, Yang, M, Lu, Y & Yi, Q 2020, Nature Communications, vol. 11, no. 1, 5902. https://doi.org/10.1038/s41467-020-19672-2
Targeting of CD38 by the tumor suppressor miR-26a serves as a novel potential therapeutic agent in multiple myeloma. Hu, Y, Liu, H, Fang, C, Li, C, Xhyliu, F, Dysert, H, Bodo, J, Habermehl, G, Russell, BE, Li, W, Chappell, M, Jiang, X, Ondrejka, SL, Hsi, ED, Maciejewski, JP, Yi, Q, Anderson, KC, Munshi, NC, Ao, G, Valent, JN, Lin, J & Zhao, J 2020, Cancer research, vol. 80, no. 10, pp. 2031-2044. https://doi.org/10.1158/0008-5472.CAN-19-1077
Enhanced lipid accumulation and metabolism are required for the differentiation and activation of tumor-associated macrophages. Su, P, Wang, Q, Bi, E, Ma, X, Liu, L, Yang, M, Qian, J & Yi, Q 2020, Cancer research, vol. 80, no. 7, pp. 1438-1450. https://doi.org/10.1158/0008-5472.CAN-19-2994